LAWRENCE, Mass., Aug. 15, 2011 /PRNewswire via COMTEX/ —
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, is celebrating Indiana University Health’s (IU Health) seventh anniversary of its program to offer home hemodialysis to patients with the NxStage System One™. IU Health started its home dialysis program by partnering with NxStage on its Investigational Device Exemption (IDE) study for U.S. Food and Drug Administration (FDA) clearance to market the System One for home use. In addition, three IU Health patients who were among the first ever to receive dialysis with the System One, are celebrating more than seven years with the therapy.
Long-time dialysis patient Rick Skiles, 57, had tried numerous treatment modalities when he learned about NxStage’s clinical trial study at IU Health in 2004. Skiles enrolled and became the first patient in Indiana to train on the NxStage System One. More than seven years later, the flexibility to do his treatments on his own time and the health benefits he has realized thanks to more frequent treatments have helped Skiles lead a liberated, healthy life. I feel extremely fortunate as a patient at IU Health to have had the opportunity to be among the first daily home hemodialysis patients, says Skiles. With the System One, I felt I got my life back, and I look forward to many active, healthy years to come with this therapy.
We applaud healthcare providers and partners such as IU Health for helping to pioneer daily home hemodialysis with the NxStage System One, said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical. Because of their leadership, enthusiasm, and continued commitment to advancing renal care, a growing number of dialysis patients like Rick are realizing the life-changing benefits possible with daily home hemodialysis.
NxStage and IU Health will host an educational event on Wednesday, August 17, 2011 at University Place Conference Center in Indianapolis to bring together the IU home dialysis patients, including Rick Skiles, and their care partners.
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company’s website at www.nxstage.com.
About Indiana University Health
Named among the Best Hospitals in America by U.S. News Media & World Report for 14 consecutive years, Indiana University Health is dedicated to providing a unified standard of preeminent, patient-centered care. A unique partnership with Indiana University School of Medicine – one of the nation’s leading medical schools – gives our highly skilled physicians access to innovative treatments using the latest research and technology. Discover the strength at iuhealth.org.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors that are discussed in NxStage’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
SOURCE NxStage Medical, Inc.